Healthcare Roundup – WuXi Bio to acquire Bayer facility, Charles River Labs teams up with Fios Genomics

医疗保健精选——药明生物收购拜耳工厂,Charles River Labs与Fios Genomics合作
Published on: January 16, 2020
Author: Amy Liu

WuXi Bio to acquire Bayer facility

  • WuXi Biologics (OTCPK:WXXWY) will take over the operations of one of Bayer’s (OTCPK:BAYRY) final drug product manufacturing plants in Leverkusen, Germany, and purchase the associated equipment, in combination with a long-term lease contract for the building.
  • The plant includes a state-of-the-art vial filling line with isolators and two lyophilizers of 20 square meters each. Based on a manufacturing agreement to be negotiated, the plant would be operated by WuXi Biologics and serve as a back-up site for the final product manufacturing of Kovaltry, an antihemophilic factor (recombinant).
  • The transaction should close in the coming months.

Charles River Labs teams up with Fios Genomics in bioinformatics

  • Charles River Laboratories (NYSE:CRL) enters into an exclusive partnership with Fios Genomics under which CRL’s customers will have access to Fios’ know-how in bioinformatics, statistics and biology to enhance their drug development efforts,  including microarrays, next-generation sequencing, proteomics, metabolomics, epigenetics and relevant metadata.

MorphoSys and Incyte team up to advance tafasitamab in $2B deal

  • MorphoSys AG (NASDAQ:MOR) inks a global collaboration and licensing agreement with Incyte (NASDAQ:INCY) to further develop and commercialize anti-CD19 monoclonal antibody tafasitamab.
  • The companies will co-commercialize tafasitamab in the U.S. with MOR leading strategy and booking all sales but equally sharing profits and losses. Ex-U.S., INCY will have exclusive commercialization rights, lead strategy and book all sales (paying royalties to MOR). INCY and MOR will share development costs associated with global and U.S.-specific studies on a 55/45 basis with INCY covering 100% of development costs for studies specific to ex-U.S. countries.
  • Under the terms of the deal, MOR will receive $750M upfront, up to $1.1B in milestones and tiered mid-teen-to-mid-twenties royalties on net sales. INCY will also make a $150M investment in MOR via the purchase of American Depositary Shares.

Owens & Minor to sell Movianto business

  • Owens & Minor (NYSE:OMI) intends to sell its European logistics business, Movianto, to EHDH Holding Group, a privately held French company.
  • The transaction is expected to close in H1 2020. Sale proceeds will be used for debt reduction.
  • Update: The sale price is ~$133M per a regulatory filing.

BioNTech to acquire Neon Therapeutics in all-stock deal

  • BioNTech SE (NASDAQ:BNTX) has agreed to acquire Neon Therapeutics (NASDAQ:NTGN) in an all-stock transaction valued at ~$67M ($2.18/share). Under the terms of the deal, Neon shareholders will receive 0.063 of a BNTX ADS for each NEON common share held.
  • Neon’s lead candidate is NEO-PTC-01, a personalized neoantigen-targeted T cell therapy.

Biotechnology Healthcare Services Life Science Pharmaceutical